Multimodal AI biomarkers: from biology to patient stratification
Multimodal AI biomarkers: from biology to patient stratification
https://dailyreporter.esmo.org/news/multimodal-ai-biomarkers-from-biology-to-patient-stratification
Publish Date: 2026-05-28 09:35:00
Source Domain: dailyreporter.esmo.org
-
Integration of Diverse Data Types: Artificial intelligence (AI) is driving the development of next-generation biomarkers by integrating histology slides, genomic and transcriptomic profiles, radiology scans, and clinical records, aiming for comprehensive biological insights.
-
Scalability and Real-Time Predictions: These AI models can generate scalable, biologically grounded insights at little added cost and produce predictions in near real-time, facilitating timely clinical decisions.
-
Multimodal AI Contributions: Each integrated modality (tissue morphology, genomics, transcriptomics, proteomics, and clinical records) provides unique information to better predict outcomes like tumor heterogeneity and immune infiltration.
-
Challenges and Validation: The success of these AI-generated biomarkers depends on their reproducibility across diverse patient populations, regulatory approval, and understanding of the underlying biological mechanisms to build clinician trust.
-
Complementing Traditional Biomarkers: These new AI biomarkers are designed to complement rather than replace existing assays, particularly in situations where tissue and sequencing data are limited.
-
Future Impact on Precision Oncology: As AI matures and more clinical data becomes accessible, multimodal AI biomarkers could become central to modern cancer care, offering advancements in diagnosis, treatment, and equity in oncology globally.
-
Role of Collaboration: Progress in this field relies on the collective efforts of academic labs, translational research groups, clinical partners, and technology companies.
-
StratifAI’s Contributions: StratifAI is leading the development of Polaris™, a multimodal AI-driven biomarker discovery platform that uses routinely available clinical data to identify novel prognostic and predictive biomarkers for individualized cancer treatment strategies.
